한글목차

방광암은 방광에 발생하는 암의 일종으로, 대부분 방광 안쪽을 덮고 있는 요로상피세포에서 발생합니다. 요로상피암은 전체 방광암의 90% 이상을 차지합니다. 전 세계적으로 방광암은 9번째로 흔한 암종입니다. 진단은 주로 침습적 시술인 방광경 검사에 의존하기 때문에 이 질환의 진단은 많은 어려움이 있고 비용이 많이 듭니다. 대부분의 방광암은 치료 가능한 초기에 진단되지만, 재발률은 상당히 높은 임베디드니다. 가장 흔한 증상은 혈뇨, 배뇨곤란, 빈뇨, 요통, 골반통 등입니다.

방광암은 크게 근비침윤성 방광암(NMIBC)과 근침윤성 방광암(MIBC)으로 나뉘며, MIBC는 다시 국소 진행성 방광암과 전이성 방광암으로 나뉘고, NMIBC는 유럽비뇨기과학회(EAU) 2021에 따라 저위험, 중위험, 고위험, 초고위험, 고위험으로 나뉩니다. FGFR 2 유전자, FGFR 3 유전자, HER 2 유전자의 유전자 변이는 방광암 발병 위험 증가와 관련이 있습니다. 의사는 이러한 유전자 변이에 따라 환자의 치료와 예후를 결정합니다.

주요 8개국에서 방광암 진단을 받은 환자 수는 2023년 279,419명에서 2033년 341,879명으로 증가해 연간 성장률(AGR)이 2.24%를 나타낼 것으로 예상되며, 2033년에는 미국이 98,184명으로 주요 8개국 중 가장 많은 방광암 진단을 받을 것으로 예상됩니다. 반면 프랑스는 18,425명으로 가장 적을 것으로 예상됩니다. 주요 8개국에서 5년간 방광암 유병자 수는 2023년 987,497명에서 2033년 1,202,635명으로 증가할 것으로 예상되며, AGR은 2.18%입니다.

이 보고서는 주요 8개 국가(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 일본, 캐나다)의 방광암 위험요인, 동반질환, 세계 및 과거 역학 동향을 개괄하고, 크론병의 진단된 발병 사례와 진단된 유병률에 대한 10년간의 역학 예측을 정리했습니다. 정리했습니다.

목차

제1장 방광암 : 주요 요약

제2장 역학

• 질병의 배경
• 위험 요인과 병존 질환
• 세계 및 과거 동향
• 주요 8개국 예측 조사 방법
• 방광암 역학 예측(2023년-2033년)
• 논의

제3장 부록

• 문헌
• 저자에 대해
• 문의

영문목차

Bladder cancer (International Classification of Diseases, 10th Revision [ICD-10] codes C67 [0-9]) is a type of cancer that begins in the urinary bladder, most often in the urothelial cells lining the inside of urinary bladder. Urothelial carcinomas make up more than 90% of all bladder cancers (American Cancer Society, 2024c). Globally, bladder cancer is the ninth most common cancer type. Diagnosis of the disease is both challenging and expensive since diagnosis relies mainly on cystoscopy, which is an invasive procedure (International Agency for Research on Cancer, 2024a). Although most bladder cancers are diagnosed at an early stage when they are highly treatable, the relapse and recurrence rates are quite high. The most common symptoms include hematuria, dysuria, frequent urination, back pain, and pelvic pain (Centers for Disease Control and Prevention, 2023; Mayo Clinic, 2024).

Bladder cancer is broadly categorized into non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). MIBC is further classified into locally advanced and metastatic bladder cancer (Cancer Research UK, 2022, 2023a). NMIBC has been categorized into risk groups by the European Association of Urology (EAU) 2021 as low, intermediate, high, and very high risk (Gontero et al., 2024). Genetic mutations in the FGFR 2, FGFR 3, and HER 2 genes are associated with an increased risk of developing bladder cancer. Based on these genetic mutations, physicians determine patient treatment and prognosis (Hayashi et al., 2020).

In the 8MM, the diagnosed incident cases of bladder cancer are expected to increase from 279,419 cases in 2023 to 341,879 cases in 2033, at an annual growth rate (AGR) of 2.24%. In 2033, the US will have the highest number of diagnosed incident cases of bladder cancer in the 8MM, with 98,184 diagnosed incident cases, whereas France will have the fewest diagnosed incident cases with 18,425 cases. In the 8MM, the five-year diagnosed prevalent cases of bladder cancer are expected to increase from 987,497 cases in 2023 to 1,202,635 cases in 2033, at an AGR of 2.18%. GlobalData epidemiologists attribute the increase in the diagnosed incident cases and five-year diagnosed prevalent cases to a certain extent with the moderately rising trend in the incidence rates in the 8MM, combined with underlying demographic changes in the respective markets.

Scope

• This report provides an overview of the risk factors, comorbidities, and global and historical epidemiological trends for bladder cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China).
• The report includes a 10-year epidemiology forecast for the diagnosed incident cases of bladder cancer and five-year diagnosed prevalent cases of bladder cancer. The diagnosed incident cases of bladder cancer are segmented by age (18 years and older) and sex.
• The diagnosed incident cases of bladder cancer are further segmented by stage at diagnosis using the American Joint Committee on Cancer (AJCC) Tumor, Node, Metastasis (TNM) staging (Stage 0a, 0is, I, II, IIIA, IIIB, IVA, and IVB), and by tumor "T" stage at diagnosis (stage Ta, Tis, T1, T2a, T2b, T3a, T3b, T4a, and T4b). They are also segmented by broad classification into NMIBC, MIBC, locally advanced, and metastatic, and by mutations and biomarkers (PD-L1 positive, FGFR 2 mutations, FGFR 3 mutations, HER2 mutations, circulating DNA [ctDNA] positive in MIBC, patients with high tumor mutational burden of more than 10 mutations per megabase, and homologous recombination [HR] deficient).
• Additionally, the diagnosed incident cases of stage Ta bladder cancer are segmented by grade (low-grade and high-grade), and the diagnosed incident cases of NMIBC are segmented by risk group (low, intermediate, high, and very high). The five-year diagnosed prevalent cases of bladder cancer are segmented by stage (Ta, Tis, T1, T2, T3, T4, and all stages), broad classification (NMIBC, MIBC, locally advanced, and metastatic), relapse or recurrence (NMIBC to MIBC, NMIBC to distant metastasis or T4 MIBC, T2 MIBC to locally advanced or T3, and T2 and T3 MIBC to distant metastasis or T4 MIBC), and by treatment (NMIBC cases with Bacillus Calmette-Guerin [BCG] failure including refractory, intolerant, unresponsive, and relapsing; metastatic bladder cancer cases that are cisplatin ineligible; and MIBC cases that are cisplatin ineligible).
• This epidemiology forecast for bladder cancer is supported by data obtained from country-specific oncology databases, peer-reviewed articles, and population-based studies.
• The forecast methodology was kept consistent across the 8MM to allow for a meaningful comparison of the forecast diagnosed incident and diagnosed prevalent cases of bladder cancer across these markets.

Reasons to Buy

The Bladder Cancer epidemiology series will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global Bladder Cancer market.
• Quantify patient populations in the global Bladder Cancer market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for Bladder Cancer therapeutics in each of the markets covered.

Table of Contents

Table of Contents

• About GlobalData

1 Bladder Cancer: Executive Summary

• 1.1 Catalyst
• 1.2 Related reports
• 1.3 Upcoming reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities.
• 2.3 Global and historical trends
• 2.4 8MM forecast methodology.
  • 2.4.1 Sources
  • 2.4.2 Forecast assumptions and methods.
  • 2.4.3 Forecast assumptions and methods: diagnosed incident cases of bladder cancer - 8MM
  • 2.4.4 Forecast assumptions and methods: diagnosed incident cases by stage at diagnosis using the AJCC TNM staging.
  • 2.4.5 Forecast assumptions and methods: diagnosed incident cases by tumor "T" stage at diagnosis.
  • 2.4.6 Forecast assumptions and methods: diagnosed incident cases of stage Ta bladder cancer by grade
  • 2.4.7 Forecast assumptions and methods: diagnosed incident cases and diagnosed prevalent cases of bladder cancer by broad classification
  • 2.4.8 Forecast assumptions and methods: diagnosed incident cases of NMIBC by risk group
  • 2.4.9 Forecast assumptions and methods: diagnosed incident cases of bladder cancer by mutations and biomarkers.
  • 2.4.10 Forecast assumptions and methods: five-year diagnosed prevalent cases of bladder cancer.
  • 2.4.11 Forecast assumptions and methods: five-year diagnosed prevalent cases of bladder cancer by tumor stage.
  • 2.4.12 Forecast assumptions and methods: five-year diagnosed prevalent cases of bladder cancer by relapse or recurrence.
  • 2.4.13 Forecast assumptions and methods: five-year diagnosed prevalent cases of bladder cancer by treatment.
• 2.5 Epidemiological forecast for bladder cancer (2023-33)
  • 2.5.1 Diagnosed incident cases of bladder cancer.
  • 2.5.2 Age-specific diagnosed incident cases of bladder cancer
  • 2.5.3 Sex-specific diagnosed incident cases of bladder cancer
  • 2.5.4 Diagnosed incident cases of bladder cancer by stage at diagnosis using the AJCC TNM staging.
  • 2.5.5 Diagnosed incident cases of bladder cancer by tumor "T" stage at diagnosis.
  • 2.5.6 Diagnosed incident cases of stage Ta bladder cancer by grade.
  • 2.5.7 Diagnosed incident cases of bladder cancer by broad classification.
  • 2.5.8 Diagnosed incident cases of NMIBC by risk group.
  • 2.5.9 Diagnosed incident cases of bladder cancer by mutations and biomarkers.
  • 2.5.10 Five-year diagnosed prevalent cases of bladder cancer
  • 2.5.11 Five-year diagnosed prevalent cases of bladder cancer by tumor stage
  • 2.5.12 Five-year diagnosed prevalent cases of bladder cancer by broad classification
  • 2.5.13 Five-year diagnosed prevalent cases of bladder cancer by relapse or recurrence
  • 2.5.14 Five-year diagnosed prevalent cases of bladder cancer by treatment
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 COVID-19 impact.
  • 2.6.3 Limitations of the analysis
  • 2.6.4 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 About the Authors
  • 3.2.1 Epidemiologist
  • 3.2.2 Reviewers
  • 3.2.3 Vice President of Disease Intelligence and Epidemiology
  • 3.2.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence
• Contact Us